AbbVie Inc (NYSE:ABBV)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Group LLC in a report issued on Friday.

A number of other equities analysts have also commented on ABBV. BMO Capital Markets reaffirmed a “market perform” rating and set a $66.00 price target on shares of AbbVie in a research report on Wednesday, May 17th. Vetr lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $71.84 target price on the stock. in a report on Monday, May 15th. Leerink Swann set a $71.00 target price on shares of AbbVie and gave the company a “hold” rating in a report on Thursday, April 20th. Finally, Deutsche Bank AG raised their target price on shares of AbbVie from $64.00 to $65.00 and gave the company a “hold” rating in a report on Friday, April 28th. Ten investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. AbbVie presently has a consensus rating of “Hold” and an average target price of $72.18.

Analyst Recommendations for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) traded down 0.39% during mid-day trading on Friday, reaching $66.06. 4,083,006 shares of the company were exchanged. The stock has a market capitalization of $105.14 billion, a price-to-earnings ratio of 17.12 and a beta of 1.57. The company’s 50 day moving average price is $65.50 and its 200-day moving average price is $63.22. AbbVie has a 12-month low of $55.06 and a 12-month high of $68.12.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, April 27th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.02. AbbVie had a net margin of 23.22% and a return on equity of 141.55%. The business had revenue of $6.54 billion for the quarter, compared to analyst estimates of $6.49 billion. During the same period last year, the firm earned $1.15 earnings per share. AbbVie’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities research analysts forecast that AbbVie will post $5.53 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AbbVie Inc (ABBV) Stock Rating Reaffirmed by Jefferies Group LLC” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/05/27/abbvie-inc-abbv-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In related news, insider Laura J. Schumacher sold 40,000 shares of AbbVie stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $65.26, for a total transaction of $2,610,400.00. Following the sale, the insider now directly owns 147,415 shares of the company’s stock, valued at approximately $9,620,302.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Carlos Alban sold 43,000 shares of AbbVie stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $67.00, for a total transaction of $2,881,000.00. Following the sale, the executive vice president now directly owns 114,745 shares in the company, valued at $7,687,915. The disclosure for this sale can be found here. Insiders have sold a total of 292,134 shares of company stock worth $19,087,407 over the last ninety days. 0.11% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of ABBV. Beacon Capital Management increased its stake in AbbVie by 150.0% in the fourth quarter. Beacon Capital Management now owns 5 shares of the company’s stock valued at $0 after buying an additional 3 shares in the last quarter. Community Bank & Trust of Waco, Texas acquired a new stake in AbbVie during the fourth quarter valued at approximately $1,819,000. First Command Financial Services Inc. increased its stake in AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock valued at $102,000 after buying an additional 99 shares in the last quarter. Acropolis Investment Management LLC acquired a new stake in AbbVie during the second quarter valued at approximately $106,000. Finally, Penserra Capital Management LLC increased its stake in AbbVie by 100.0% in the third quarter. Penserra Capital Management LLC now owns 1,764 shares of the company’s stock valued at $111,000 after buying an additional 882 shares in the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

12 Month Chart for NYSE:ABBV

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.